Angion Biomedica Corp.
ANGNNASDAQHealthcare
$1.00
+$0.00(+0.00%)
Market Cap$30113700
P/E Ratio—
52W High$20.4
52W Low$1.0
Angion Biomedica Corp. (ANGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANGN · earnings · updated Jun 10, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 13, 2023EPS Actual
-$1.27
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 13, 2023
After Market Close
ANGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | May 8, 2024 | — | — | — | — | — | — |
| — Q4 FY2023 | Nov 13, 2023 | — | -$1.27 | — | — | — | — |
| ▼ Q3 FY2023 | Aug 21, 2023 | $0.57 | -$2.44 | -527.6% | — | — | — |
| ▲ Q2 FY2023 | May 10, 2023 | -$0.54 | -$0.15 | +72.2% | — | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | -$0.38 | — | — | — | — |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$0.36 | -$0.21 | +41.7% | — | — | — |
| ▲ Q3 FY2022 | Aug 15, 2022 | -$0.46 | -$0.30 | +34.8% | $0.00B | — | — |
| ▼ Q2 FY2022 | May 16, 2022 | -$0.44 | -$0.48 | -9.1% | $0.00B | $0.00B | +13.2% |
Q2 FY2024
May 8, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 13, 2023
EPS Actual
-$1.27
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 21, 2023Miss
EPS Actual
-$2.44
EPS Est.
$0.57
EPS Surpr.
-527.6%
Revenue
—
Q2 FY2023
May 10, 2023Beat
EPS Actual
-$0.15
EPS Est.
-$0.54
EPS Surpr.
+72.2%
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
-$0.38
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$0.21
EPS Est.
-$0.36
EPS Surpr.
+41.7%
Revenue
—
Q3 FY2022
Aug 15, 2022Beat
EPS Actual
-$0.30
EPS Est.
-$0.46
EPS Surpr.
+34.8%
Revenue
$0.00B
Q2 FY2022
May 16, 2022Miss
EPS Actual
-$0.48
EPS Est.
-$0.44
EPS Surpr.
-9.1%
Revenue
$0.00B
No analyst estimates available for ANGN.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 13, 2023 | — | $1.00 | — | — |
| ▼ Q3 FY2023 | Aug 21, 2023 | -527.6% | $1.00 | — | — |
| ▲ Q2 FY2023 | May 10, 2023 | +72.2% | $0.81 | $0.84 | +3.70% |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.81 | $0.87 | +7.43% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +41.7% | $0.97 | $0.90 | -7.08% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +34.8% | $1.03 | $1.04 | +0.97% |
| ▼ Q2 FY2022 | May 16, 2022 | -9.1% | $1.30 | $1.30 | +0.00% |
| — Q4 FY2021 | Dec 31, 2021 | — | $2.87 | $2.90 | +1.05% |
Q4 FY2023—
Report Date
Nov 13, 2023
EPS Beat/Miss
—
Price Before
$1.00
Price After
—
Q3 FY2023—
Report Date
Aug 21, 2023
EPS Beat/Miss
-527.6%
Price Before
$1.00
Price After
—
Q2 FY2023+3.70%
Report Date
May 10, 2023
EPS Beat/Miss
+72.2%
Price Before
$0.81
Price After
$0.84
Q4 FY2022+7.43%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.81
Price After
$0.87
Q4 FY2022-7.08%
Report Date
Nov 14, 2022
EPS Beat/Miss
+41.7%
Price Before
$0.97
Price After
$0.90
Q3 FY2022+0.97%
Report Date
Aug 15, 2022
EPS Beat/Miss
+34.8%
Price Before
$1.03
Price After
$1.04
Q2 FY2022+0.00%
Report Date
May 16, 2022
EPS Beat/Miss
-9.1%
Price Before
$1.30
Price After
$1.30
Q4 FY2021+1.05%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$2.87
Price After
$2.90
Avg Beat Reaction-0.80%
Avg Miss Reaction+0.00%
Beat Rate3 / 8 quarters
Largest Move+7.43% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANGN ends December
Angion Biomedica Corp. (ANGN) most recently reported earnings on November 13, 2023 for Q4 FY2023, posting EPS of $-1.27 (in line with the analyst consensus of —).
Each quarter, investors track ANGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANGN earnings · 4 questionsAngion Biomedica Corp.'s next earnings report is expected around TBD. ANGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANGN historically reports after market close (AMC).
ANGN earnings datewhen is ANGN earningsANGN next earnings datewhen does ANGN report earningsANGN earnings calendar
▸ Source: FMP · Angion Biomedica Corp. SEC filings · US GAAP · Angion Biomedica Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026